Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Calidi Biotherapeutics's Sloan Ratio for the quarter that ended in Mar. 2026 was -6.07%.
As of Mar. 2026, Calidi Biotherapeutics has a Sloan Ratio of -6.07%, indicating the company is in the safe zone and there is no funny business with accruals.
Calidi Biotherapeutics (AMEX:CLDI) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2026, Calidi Biotherapeutics has a Sloan Ratio of -6.07%, indicating the company is in the safe zone and there is no funny business with accruals.
Calidi Biotherapeutics Sloan Ratio % Related Terms
Calidi Biotherapeutics Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Calidi Biotherapeutics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Calidi Biotherapeutics Sloan Ratio % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Calidi Biotherapeutics's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Calidi Biotherapeutics's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Calidi Biotherapeutics's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was -5.715 (Jun. 2025 ) + -5.149 (Sep. 2025 ) + -4.056 (Dec. 2025 ) + -4.108 (Mar. 2026 ) = $-19.03 Mil.
Calidi Biotherapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was -4.88 (Jun. 2025 ) + -4.238 (Sep. 2025 ) + -5.044 (Dec. 2025 ) + -4.116 (Mar. 2026 ) = $-18.28 Mil.
Calidi Biotherapeutics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 was -0.057 (Jun. 2025 ) + -0.027 (Sep. 2025 ) + -0.079 (Dec. 2025 ) + -0.005 (Mar. 2026 ) = $-0.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Calidi Biotherapeutics (CLDI) has a Sloan Ratio % of -6.07% as of Mar. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Calidi Biotherapeutics and its competitors.
Is Calidi Biotherapeutics' Sloan Ratio % too high?
Calidi Biotherapeutics' current Sloan Ratio % is -6.07%. Overall, Calidi Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' Sloan Ratio % compare to DCOY and CDT?
Calidi Biotherapeutics' Sloan Ratio % of -6.07% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Biotechnology company?
A good Sloan Ratio % depends on the Biotechnology industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Calidi Biotherapeutics and its competitors. Calidi Biotherapeutics's current Sloan Ratio % is -6.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current Sloan Ratio % of -6.07%. The current Sloan Ratio % is -6.07%. Calidi Biotherapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current Sloan Ratio % is -6.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
12GF Score
Get the complete analysis for CLDI
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDI has been successfully added to your 
